NasdaqCM - Nasdaq Real Time Price USD
Cardiff Oncology, Inc. (CRDF)
3.5550
+0.2050
+(6.12%)
As of 2:05:01 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -0.2 | -0.21 | -0.85 | -0.99 |
| Low Estimate | -0.22 | -0.25 | -0.98 | -1.14 |
| High Estimate | -0.18 | -0.17 | -0.72 | -0.85 |
| Year Ago EPS | -0.26 | -0.25 | -0.95 | -0.85 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | 100k | 100k | 389.57k | 285.71k |
| Low Estimate | -- | -- | 100k | -- |
| High Estimate | 200k | 200k | 600k | 600k |
| Year Ago Sales | 163k | 165k | 683k | 389.57k |
| Sales Growth (year/est) | -38.65% | -39.39% | -42.96% | -26.66% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.25 | -0.27 | -0.25 | -0.19 |
| EPS Actual | -0.26 | -0.25 | -0.21 | -0.2 |
| Difference | -0.01 | 0.02 | 0.04 | -0.01 |
| Surprise % | -5.40% | 8.54% | 15.15% | -7.53% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.2 | -0.21 | -0.85 | -0.99 |
| 7 Days Ago | -0.2 | -0.21 | -0.85 | -0.99 |
| 30 Days Ago | -0.19 | -0.21 | -0.82 | -0.96 |
| 60 Days Ago | -0.2 | -0.22 | -0.86 | -1.04 |
| 90 Days Ago | -0.2 | -0.21 | -0.83 | -0.98 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 1 |
| Up Last 30 Days | -- | 1 | 1 | 2 |
| Down Last 7 Days | 1 | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CRDF | 21.54% | 16.00% | 10.11% | -16.39% |
| S&P 500 | 13.08% | 2.49% | 7.56% | 13.96% |
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/9/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/28/2025 |
| Maintains | Piper Sandler: Overweight to Overweight | 12/13/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/8/2024 |
| Initiated | Craig-Hallum: Buy | 9/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/6/2024 |
Related Tickers
IMUX Immunic, Inc.
0.7070
+1.00%
RVPH Reviva Pharmaceuticals Holdings, Inc.
0.8016
-8.89%
TRVI Trevi Therapeutics, Inc.
6.15
-2.61%
VSTM Verastem, Inc.
5.98
-0.67%
MLTX MoonLake Immunotherapeutics
49.61
+20.53%
LXEO Lexeo Therapeutics, Inc.
2.9000
+6.62%
ORIC ORIC Pharmaceuticals, Inc.
8.54
+0.77%
CTMX CytomX Therapeutics, Inc.
2.5801
+2.79%
URGN UroGen Pharma Ltd.
5.04
+4.13%
ITOS iTeos Therapeutics, Inc.
10.17
+1.60%